Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
93.34
-1.00 (-1.06%)
At close: Jul 6, 2026, 4:00 PM EDT
95.27
+1.93 (2.07%)
After-hours: Jul 6, 2026, 6:08 PM EDT
Dianthus Therapeutics Employees
Dianthus Therapeutics had 92 employees as of December 31, 2025. The number of employees increased by 14 or 17.95% compared to the previous year.
Employees
92
Change (1Y)
14
Growth (1Y)
17.95%
Revenue / Employee
$14,522
Profits / Employee
-$1,887,609
Market Cap
5.10B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 92 | 14 | 17.95% |
| Dec 31, 2024 | 78 | 25 | 47.17% |
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Jun 30, 2023 | 43 | - | - |
| Mar 31, 2023 | 32 | - | - |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| Travere Therapeutics | 497 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Celcuity | 155 |
| Definium Therapeutics | 106 |
| Erasca | 103 |
DNTH News
- 4 days ago - Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 7 days ago - Dianthus initiates EMERGE trial of claseprubart - TheFly
- 7 days ago - Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis - GlobeNewsWire
- 24 days ago - Dianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James - TheFly
- 24 days ago - Dianthus reports additional data from Part A of CAPTIVITY study - TheFly
- 24 days ago - Dianthus rises 7.7% - TheFly
- 26 days ago - Dianthus price target raised to $132 from $110 at Jefferies - TheFly
- 26 days ago - Dianthus falls -16.0% - TheFly